XML 70 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Debt (Additional Information) (Details) - USD ($)
 12 Months Ended
Sep. 30, 2023
Sep. 21, 2023
Jul. 01, 2023
Jun. 27, 2023
Apr. 30, 2023
Mar. 21, 2023
Dec. 31, 2023
Oct. 11, 2023
Sep. 25, 2023
Dec. 31, 2022
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt         $ 25,000,000          
Debt conversion price             $ 8      
Debt Instrument Redemption             The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days’ prior written notice to Yorkville (the “Redemption Notice”), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.      
Common stock, shares issued             160,084,250   474,683 141,348,856
Maximum [Member]                    
Debt Instrument [Line Items]                    
Debt conversion price               $ 2    
Minimum [Member]                    
Debt Instrument [Line Items]                    
Debt conversion price               $ 0.5    
Oramed Note                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt $ 101,900,000                  
Estimated fair value             $ 104,100,000      
Securities Purchase Agreement [Member]                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt           $ 25,000,000        
Debt instrument, description             The Yorkville SPA provides that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0 million upon the signing of the Yorkville SPA, which was funded on March 21, 2023; (ii) $7.5 million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the “Securities Act”), which was funded on April 11, 2023; and (iii) $7.5 million at the time such registration statement was declared effective by the SEC, which was funded on April 20, 2023.      
Debt instrument, interest rate           7.00%        
Debt maturity date           Dec. 21, 2023 Mar. 15, 2024      
Debt conversion price           $ 8        
Debt Instrument Principal Amount, Percentage           5.00%        
Debt payment terms             The Company has the option to repay either (i) in cash, with premium equal to 5% in respect of the principal amount of such payment, or (ii) by submitting a notice for an advance under the A&R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i) or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.      
Convertible Debentures Issued Percent           96.00%        
Redemption Premium             10.00%      
Securities Purchase Agreement [Member] | First installment [Member]                    
Debt Instrument [Line Items]                    
Repayment of debt prinnciple installment   $ 5,000,000                
Securities Purchase Agreement [Member] | Second Installment [Member]                    
Debt Instrument [Line Items]                    
Repayment of debt prinnciple installment   15,000,000                
Securities Purchase Agreement [Member] | Third Installment [Member]                    
Debt Instrument [Line Items]                    
Repayment of debt prinnciple installment   20,000,000                
Securities Purchase Agreement [Member] | Oramed Note                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt   101,900,000                
Debt instrument, description             Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1) greater of (x) 4% and (y) Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. If the outstanding principal has not been fully repaid by March 21, 2024, an exit fee of approximately $3.1 million becomes due upon repayment. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i) Term SOFR plus 15% or (ii) the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April 1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).      
Estimated fair value             $ 104,100,000      
Debt Repayment Exit Fee   $ 3,100,000                
Debt instrument, interest rate   4.00%                
Debt maturity date   Mar. 21, 2025                
Debt instrument, owned, percentage   50.00%                
Debt instrument, default interest rate   15.00%                
Debt instrument, percentage of interest accrued on principal amount   50.00%                
Debt repayment, percentage of mandatory default rate of principal amount   125.00%                
Debt repayment, percentage of mandatory default rate of accrued and unpaid interest   100.00%                
Percentage of usage of cash proceeds from cash sweep financing   70.00%                
Securities Purchase Agreement [Member] | Oramed Note | Monthly Basis [Member]                    
Debt Instrument [Line Items]                    
Debt instrument, interest rate   8.50%                
Securities Purchase Agreement [Member] | Oramed Note | First installment [Member]                    
Debt Instrument [Line Items]                    
Debt maturity date   Mar. 21, 2025                
Securities Purchase Agreement [Member] | Oramed Note | Second Installment [Member]                    
Debt Instrument [Line Items]                    
Debt maturity date   Dec. 21, 2023                
Securities Purchase Agreement [Member] | Oramed Note | Third Installment [Member]                    
Debt Instrument [Line Items]                    
Debt maturity date   Mar. 21, 2024                
Securities Purchase Agreement [Member] | Oramed Note | Fourth Installment [Member]                    
Debt Instrument [Line Items]                    
Debt maturity date   Jun. 21, 2024                
Securities Purchase Agreement [Member] | Oramed Note | Five Installment [Member]                    
Debt Instrument [Line Items]                    
Debt maturity date   Sep. 21, 2024                
Securities Purchase Agreement [Member] | Oramed Note | Six Installment [Member]                    
Debt Instrument [Line Items]                    
Debt maturity date   Dec. 21, 2024                
Tranche One | Securities Purchase Agreement [Member]                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt           $ 10,000,000        
Tranche Two | Securities Purchase Agreement [Member]                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt           7,500,000        
Tranche Three | Securities Purchase Agreement [Member]                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt           $ 7,500,000        
A&R Yorkville Purchase Agreement                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt         15,000,000          
Net cash proceeds         $ 14,400,000          
Convertible Debentures Repaid             $ 15,600,000      
Common Stock at a conversion price             $ 8      
Outstanding debt instrument             $ 4,400,000      
Change in fair value             $ 700,000      
Servicing Liability, Fair Value, Change in Fair Value, Other, Statement of Income or Comprehensive Income [Extensible Enumeration]             Operating Costs and Expenses      
Outstanding principal amount             $ 5,000,000      
Common stock, shares issued             632,431      
Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Aggregate Principle amount of issued debt             $ 75,000,000      
Termination fees             0.50%      
Facility cap maximum       95.00%            
Facility cap minimum       85.00%            
Outstanding debt instrument       $ 250,000            
Cash on hand             $ 1,000,000      
Outstanding principal amount             $ 17,000,000      
Accounts receivable revolving loan facility in an aggregate amount   $ 30,000,000   $ 30,000,000            
Line Of Credit Facility Interest Rate     1.50%